These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 34464596)

  • 1. A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants.
    Schmitz AJ; Turner JS; Liu Z; Zhou JQ; Aziati ID; Chen RE; Joshi A; Bricker TL; Darling TL; Adelsberg DC; Altomare CG; Alsoussi WB; Case JB; VanBlargan LA; Lei T; Thapa M; Amanat F; Jeevan T; Fabrizio T; O'Halloran JA; Shi PY; Presti RM; Webby RJ; Krammer F; Whelan SPJ; Bajic G; Diamond MS; Boon ACM; Ellebedy AH
    Immunity; 2021 Sep; 54(9):2159-2166.e6. PubMed ID: 34464596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A public vaccine-induced human antibody protects against SARS-CoV-2 and emerging variants.
    Schmitz AJ; Turner JS; Liu Z; Aziati ID; Chen RE; Joshi A; Bricker TL; Darling TL; Adelsberg DC; Alsoussi WB; Case JB; Lei T; Thapa M; Amanat F; O'Halloran JA; Shi PY; Presti RM; Krammer F; Bajic G; Whelan SPJ; Diamond MS; Boon ACM; Ellebedy AH
    bioRxiv; 2021 Mar; ():. PubMed ID: 33791696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies.
    Zhou H; Dcosta BM; Samanovic MI; Mulligan MJ; Landau NR; Tada T
    mBio; 2021 Aug; 12(4):e0138621. PubMed ID: 34311587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
    Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
    J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
    Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
    Front Immunol; 2021; 12():747830. PubMed ID: 34858404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel Bacterial Protease Inhibitor Adjuvant in RBD-Based COVID-19 Vaccine Formulations Containing Alum Increases Neutralizing Antibodies, Specific Germinal Center B Cells and Confers Protection Against SARS-CoV-2 Infection in Mice.
    Coria LM; Saposnik LM; Pueblas Castro C; Castro EF; Bruno LA; Stone WB; Pérez PS; Darriba ML; Chemes LB; Alcain J; Mazzitelli I; Varese A; Salvatori M; Auguste AJ; Álvarez DE; Pasquevich KA; Cassataro J
    Front Immunol; 2022; 13():844837. PubMed ID: 35296091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation.
    Lederer K; Castaño D; Gómez Atria D; Oguin TH; Wang S; Manzoni TB; Muramatsu H; Hogan MJ; Amanat F; Cherubin P; Lundgreen KA; Tam YK; Fan SHY; Eisenlohr LC; Maillard I; Weissman D; Bates P; Krammer F; Sempowski GD; Pardi N; Locci M
    Immunity; 2020 Dec; 53(6):1281-1295.e5. PubMed ID: 33296685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.
    Wang Z; Schmidt F; Weisblum Y; Muecksch F; Barnes CO; Finkin S; Schaefer-Babajew D; Cipolla M; Gaebler C; Lieberman JA; Oliveira TY; Yang Z; Abernathy ME; Huey-Tubman KE; Hurley A; Turroja M; West KA; Gordon K; Millard KG; Ramos V; Da Silva J; Xu J; Colbert RA; Patel R; Dizon J; Unson-O'Brien C; Shimeliovich I; Gazumyan A; Caskey M; Bjorkman PJ; Casellas R; Hatziioannou T; Bieniasz PD; Nussenzweig MC
    Nature; 2021 Apr; 592(7855):616-622. PubMed ID: 33567448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 Omicron boosting induces de novo B cell response in humans.
    Alsoussi WB; Malladi SK; Zhou JQ; Liu Z; Ying B; Kim W; Schmitz AJ; Lei T; Horvath SC; Sturtz AJ; McIntire KM; Evavold B; Han F; Scheaffer SM; Fox IF; Mirza SF; Parra-Rodriguez L; Nachbagauer R; Nestorova B; Chalkias S; Farnsworth CW; Klebert MK; Pusic I; Strnad BS; Middleton WD; Teefey SA; Whelan SPJ; Diamond MS; Paris R; O'Halloran JA; Presti RM; Turner JS; Ellebedy AH
    Nature; 2023 May; 617(7961):592-598. PubMed ID: 37011668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ipsilateral or contralateral boosting of mice with mRNA vaccines confers equivalent immunity and protection against a SARS-CoV-2 Omicron strain.
    Ying B; Liang C-Y; Desai P; Scheaffer SM; Elbashir SM; Edwards DK; Thackray LB; Diamond MS
    J Virol; 2024 Sep; 98(9):e0057424. PubMed ID: 39194250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.
    Collier DA; De Marco A; Ferreira IATM; Meng B; Datir RP; Walls AC; Kemp SA; Bassi J; Pinto D; Silacci-Fregni C; Bianchi S; Tortorici MA; Bowen J; Culap K; Jaconi S; Cameroni E; Snell G; Pizzuto MS; Pellanda AF; Garzoni C; Riva A; ; Elmer A; Kingston N; Graves B; McCoy LE; Smith KGC; Bradley JR; Temperton N; Ceron-Gutierrez L; Barcenas-Morales G; ; Harvey W; Virgin HW; Lanzavecchia A; Piccoli L; Doffinger R; Wills M; Veesler D; Corti D; Gupta RK
    Nature; 2021 May; 593(7857):136-141. PubMed ID: 33706364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom.
    Wu J; Zhang L; Zhang Y; Wang H; Ding R; Nie J; Li Q; Liu S; Yu Y; Yang X; Duan K; Qu X; Wang Y; Huang W
    Front Immunol; 2021; 12():687869. PubMed ID: 34220844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes.
    Tada T; Dcosta BM; Samanovic MI; Herati RS; Cornelius A; Zhou H; Vaill A; Kazmierski W; Mulligan MJ; Landau NR
    mBio; 2021 Jun; 12(3):e0069621. PubMed ID: 34060334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies.
    Fernández J; Bruneau N; Fasce R; Martín HS; Balanda M; Bustos P; Ulloa S; Mora J; Ramírez E
    J Med Virol; 2022 Jan; 94(1):399-403. PubMed ID: 34460119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and Analysis of Monoclonal Antibodies with Neutralizing Activity against Diverse SARS-CoV-2 Variants.
    Ishimaru H; Nishimura M; Tjan LH; Sutandhio S; Marini MI; Effendi GB; Shigematsu H; Kato K; Hasegawa N; Aoki K; Kurahashi Y; Furukawa K; Shinohara M; Nakamura T; Arii J; Nagano T; Nakamura S; Sano S; Iwata S; Okamura S; Mori Y
    J Virol; 2023 Jun; 97(6):e0028623. PubMed ID: 37191569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
    Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
    Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of human post-vaccination SARS-CoV-2 standard reference sera.
    Xiang J; Katz L; Winokur PL; Chaudhary A; Digmann B; Bradford R; Rashid S; Ghosh S; Robertson A; Menetski J; Xu M; Gao P; Chen CZ; Lee T; Poelaert B; Eastman RT; Hall MD; Stapleton JT
    J Immunol Methods; 2024 Jul; 530():113698. PubMed ID: 38823574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spike mutation D614G alters SARS-CoV-2 fitness.
    Plante JA; Liu Y; Liu J; Xia H; Johnson BA; Lokugamage KG; Zhang X; Muruato AE; Zou J; Fontes-Garfias CR; Mirchandani D; Scharton D; Bilello JP; Ku Z; An Z; Kalveram B; Freiberg AN; Menachery VD; Xie X; Plante KS; Weaver SC; Shi PY
    Nature; 2021 Apr; 592(7852):116-121. PubMed ID: 33106671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.